XRD-0394

News alerts, weekly reports and conference planners

Company:

XRad Therap

Drug class:

DNA PK inhibitor, ATM kinase inhibitor

A Phase Ia clinical trial (NCT05002140) with XRD-0394 in combination with RT has completed. These results provide a rationale for future clinical trials with XRD-0394 in combination with RT, PARP inhibitors and targeted delivery of topoisomerase I inhibitors.

1 month ago

Journal

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

XRD-0394

4ms

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (clinicaltrials.gov)

P1, N=12, Completed, XRad Therapeutics Inc | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023

4 months ago

Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases

XRD-0394

10ms

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (clinicaltrials.gov)

P1, N=11, Active, not recruiting, XRad Therapeutics Inc | Recruiting --> Active, not recruiting | N=38 --> 11

10 months ago

Enrollment closed • Enrollment change • Combination therapy • Metastases

XRD-0394